Positives

• Patients using LL-37 for suspected chronic infection or unresolved inflammation describe gradual improvement in energy, sinus symptoms, or GI flare frequency over 8-12 weeks.
  
  
• One patient reported noticing better tolerance to recurring infections within the first month of off-label clinician-supervised use.
  
  

Negatives

• Patients trying LL-37 sometimes report a die-off-style flare in the first weeks that they find hard to distinguish from worsening.
  
  
• Some patients describe no clear response and stop, particularly when the underlying infection picture was never confirmed.
  
  

Hurdles & Side Effects

• LL-37 is not FDA-approved for Long COVID; access depends on a clinician willing to prescribe off-label through a compounding pharmacy.
  
  
• Cost is significant and patients describe difficulty finding clinicians experienced enough to dose and monitor it appropriately.